cefpodoxime

EsbL ; Escherichia coli







10 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35451880 In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. 2022 Apr 1
2 31949454 Prevalence and antibiotic resistance pattern of extended-spectrum beta-lactamase-producing Escherichia coli in clinical specimens. 2019 1
3 28368864 Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China. 2017 Mar 31 1
4 26511749 Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. 2016 Jul 1
5 22264296 Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae. 2012 Dec 1
6 20085420 Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County. 2010 Apr 1
7 19949753 Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. 2009 Aug 2
8 12517841 Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. 2003 Jan 2
9 12532575 Susceptibility patterns of Escherichia coli: prevalence of multidrug-resistant isolates and extended spectrum beta-lactamase phenotype. 2002 Sep 3
10 11146252 Cefpodoxime screening of Escherichia coli and Klebsiella spp. by Vitek for detection of organisms producing extended-spectrum beta-lactamases. 2000 Dec 1